T-cell replete cord vs comparator cohort incidence of chronic GvHD. Univariable analysis shows a significantly lower risk of developing chronic GvHD for T-replete cord recipients compared with the patients in the comparator group (HR, 0.25 [95% CI, 0.10-0.62]; P = .003), with a cumulative incidence of 5% (95% CI, 0.02-0.11) for the T-replete cord patients compared with 19.4% (95% CI, 0.15-0.25) for the comparator. GvHD, graft versus host disease.